Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy

[1]  G. Pawelec,et al.  Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines , 2008, Cancer Immunology, Immunotherapy.

[2]  D. Morton,et al.  Vaccine therapy for melanoma: current status and future directions. , 2007, Vaccine.

[3]  F. Garrido,et al.  HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination , 2007, Cancer Immunology, Immunotherapy.

[4]  F. Garrido,et al.  Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines , 2007, BMC Cancer.

[5]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[6]  F. Garrido,et al.  LOH at 6p21.3 region and HLA class altered phenotypes in bladder carcinomas , 2006, Immunogenetics.

[7]  I. Ellis,et al.  Total loss of MHC class I is an independent indicator of good prognosis in breast cancer , 2005, International journal of cancer.

[8]  F. Lozupone,et al.  Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? , 2005, Expert opinion on biological therapy.

[9]  S. Menzies,et al.  Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma , 2005, Cancer Immunology, Immunotherapy.

[10]  F. Garrido,et al.  Involvement of the chaperone tapasin in HLA‐B44 allelic losses in colorectal tumors , 2005, International journal of cancer.

[11]  P. Coulie,et al.  Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Rosenberg,et al.  Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Paul,et al.  Gene-based vaccines and immunotherapeutics , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  P. Slootweg,et al.  High level of chromosome 15 aneuploidy in head and neck squamous cell carcinoma lesions identified by FISH analysis: limited value of beta2-microglobulin LOH analysis. , 2004, Tissue antigens.

[15]  D. Berd.  M-Vax: an autologous, hapten-modified vaccine for human cancer , 2004, Expert review of vaccines.

[16]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[17]  R. Rees,et al.  Escape from immunotherapy: possible mechanisms that influence tumor regression/progression , 2004, Cancer Immunology, Immunotherapy.

[18]  Federico Garrido,et al.  The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape , 2004, Cancer Immunology, Immunotherapy.

[19]  F. Garrido,et al.  Multiple mechanisms are responsible for the alteration in the expression of HLA class I antigens in melanoma , 2003 .

[20]  Euijae Kim,et al.  A Single Polymorphic Residue Within the Peptide-Binding Cleft of MHC Class I Molecules Determines Spectrum of Tapasin Dependence , 2003, The Journal of Immunology.

[21]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[22]  Jonathan J. Lewis,et al.  Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Dalerba,et al.  Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction , 2002, Immunological reviews.

[24]  S. Markovic,et al.  Challenges in the development of effective peptide vaccines for cancer. , 2002, Mayo Clinic proceedings.

[25]  B. Seliger,et al.  HLA class I antigen abnormalities and immune escape by malignant cells. , 2002, Seminars in cancer biology.

[26]  F. Garrido,et al.  Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy. , 2001, Tissue antigens.

[27]  P. Coulie,et al.  Biological and clinical developments in melanoma vaccines , 2001, Expert opinion on biological therapy.

[28]  M. Gore,et al.  Interferon‐alpha (IFN‐α) stimulates anti‐melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC) , 2000, Clinical and experimental immunology.

[29]  S. Pettit,et al.  Selection of metastatic tumour phenotypes by host immune systems , 1999, The Lancet.

[30]  M. Griffioen,et al.  Role of the interferon-stimulated response element in HLA-B downregulation in human melanoma cell lines , 1999, Immunogenetics.

[31]  F. Brasseur,et al.  Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. , 1998, Tissue antigens.

[32]  F. Garrido,et al.  Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line , 1998, Cancer Immunology, Immunotherapy.

[33]  P. Stern,et al.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.

[34]  F. Marincola,et al.  Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. , 1994, Journal of immunology.

[35]  J U Gutterman,et al.  Cytokine therapeutics: lessons from interferon alpha. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Vilella,et al.  Biochemical and serological characterization of a public antigenic determinant present on HLA-B molecules. , 1990, Tissue antigens.

[37]  H. Ploegh,et al.  Suppression of class I human histocompatibility leukocyte antigen by c- myc is locus specific , 1989, The Journal of experimental medicine.

[38]  F. Esteban,et al.  HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. , 1989, British Journal of Cancer.

[39]  H. Ploegh,et al.  Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. , 1986, Journal of immunology.

[40]  J. Strominger,et al.  Evidence for a shared HLA-A intralocus determinant defined by monoclonal antibody 131 , 1985, The Journal of experimental medicine.

[41]  F. Garrido,et al.  Role of altered expression of HLA class I molecules in cancer progression. , 2007, Advances in experimental medicine and biology.

[42]  F. Garrido,et al.  MHC class I antigens and immune surveillance in transformed cells. , 2007, International review of cytology.

[43]  I. Ellis,et al.  Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis , 2006, International journal of cancer.

[44]  R. Vilella,et al.  Identification of the amino acid residues defining an intralocus determinant in the α1 domain of HLA-A molecules , 2006, Immunogenetics.

[45]  F. Garrido,et al.  Immunoselection by T lymphocytes generates repeated MHC class I‐deficient metastatic tumor variants , 2001, International Journal of Cancer.

[46]  F. Garrido,et al.  MHC antigens and tumor escape from immune surveillance. , 2001, Advances in cancer research.

[47]  L. Schuchter,et al.  Metastatic melanoma , 2001, Current treatment options in oncology.

[48]  F. Garrido,et al.  MHC antigens and malignancy. , 1986, Nature.